A medical device manufacturer that has specialized in developing humidification systems to improve breathing for people with respiratory difficulties such as asthma, croup and COPD has raised $26.4 million, according to a Form D filing with the U.S. Securities and Exchange Commission.
Last year, Vapotherm, which has offices in Stevensville, Maryland, said it would expand to Exeter, New Hampshire. It received 510(k) clearance from the U.S. Food and Drug Administration two years ago for its Precision Flow Heliox device — a high-flow humidification system designed for use with blended helium oxygen gas mixtures or Heliox. Heliox is used in respiratory applications such as upper airway obstruction, asthma, croup and COPD.
Its respiratory care devices are used by hospitals and for home care. The company’s high-flow humidification system is used to treat adults as well as premature infants with infant respiratory distress syndrome to avoid the need for intubation and to reduce the risk of retinopathy.
Investors in the company include GE Asset Management, Cross Creek Capital and Integral Capital Partners, QuestMark Partners and Kaiser Permanente Ventures.
